Brainstorm Cell Therapeutics Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-5.0M | $-5.0M | $-8.5M | $-9.2M | $-4.9M | $-3.4M | $-3.9M | $-2.4M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $85.0K | $77.0K | $87.0K | $106.0K | $97.0K | $157.0K | $153.0K | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $616.0K | $756.0K | $943.0K | $1.2M | $872.0K | $781.0K | $1.1M | $388.0K |
| Net Cash from Operating Activities | $-2.4M | $-5.9M | $-7.4M | $-4.5M | $-4.1M | $-2.9M | $-2.2M | $-2.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $180.0K | $103.0K | $45.0K | $161.0K | $108.0K | $90.0K | $48.0K | $5.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $4.0M | $6.0M | — | $-4.5M | $2.7M | $-2.8M | $-64.0K | $1.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $314.0K | $0 | — | $9.7M | $3.6M | $5.2M | $4.1M | $2.2M |
| Net Change in Cash | $1.9M | $119.0K | $-3.8M | $748.0K | $2.2M | $-606.0K | $1.8M | $92.0K |
| Free Cash Flow | $-2.5M | $-6.0M | $-7.5M | $-4.6M | $-4.2M | $-3.0M | $-2.3M | $-2.1M |